Results of competition for radioligand binding by SDX-9402 at different receptors, to assess the selectivity of the MetAP2 inhibitor against known drug targets.
No takes yet. Share an insight, caveat, or question.
Cornelius et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: